Supplemental Figures

Dutta, R. et al.

A bivalent compound targeting CCR5 and the mu opioid receptor treats inflammatory arthritis pain in mice without inducing pharmacologic tolerance.

Supplemental Figure Legends

Supplemental Figure 1: Structure of MCC22. MCC22 is a bivalent pharmacophore comprising a mu opioid receptor (MOR) agonist and a CCR5 antagonist joined by a 22-atom spacer.

Supplemental Figure 2: Representative histologic sections. The images show histologic sections of ankles from non-arthritic control animals and arthritic K/B.g7 mice treated with vehicle (DMSO) or daily MCC22 for 9 days (8 μmol/kg/dose). Photomicrographs were obtained with a 4x objective. Scale bars indicate 500 microns.

Supplemental Figure 1



Mu opioid receptor (MOR) agonist

22-atom spacer

CCR5 antagonist

Supplemental Figure 2